This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechnology: Archive
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
by Ekta Bagri
QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.
QUREPositive Net Change SRPTNegative Net Change PTCTPositive Net Change
biotechnology biotechs pharmaceuticals
HRMY Posts Preliminary Q2 Revenues, Announces CFO Transition
by Zacks Equity Research
Harmony Biosciences posts preliminary Q2 2026 Wakix revenues of about $261M, up 30% year over year, while reaffirming full-year guidance despite a CFO transition.
HRMYPositive Net Change NVAXNegative Net Change LQDAPositive Net Change
biotechnology biotechs pharmaceuticals
Can Novartis' Fabhalta Strengthen Its Nephrology Franchise?
by Ekta Bagri
NVS wins full FDA approval for Fabhalta in IgA nephropathy after phase III data shows slower kidney function decline, strengthening its nephrology portfolio.
NVSPositive Net Change VRTXNegative Net Change TVTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
AWHL vs. MYGN: Which Women's Health Diagnostics Stock is Better Now?
by Debanjana Dey
Aspira and Myriad Genetics take different approaches to women's health diagnostics, but which stock looks more compelling now? Let's dive in.
MYGNNegative Net Change AWHLNegative Net Change
biotechnology biotechs cancer medical medical-devices oncology-screening
NVO Stock Up on EC Approval of Wegovy Pill to Treat Obesity
by Zacks Equity Research
Novo Nordisk wins EC approval for a once-daily oral Wegovy pill for obesity, expanding its EU franchise with the first GLP-1 tablet for weight management.
NVONegative Net Change LLYPositive Net Change NVAXNegative Net Change LQDAPositive Net Change
biotechnology medical pharmaceuticals
Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
by Ekta Bagri
Denali Therapeutics gains FDA approval for Avlayah, but pipeline setbacks and partner exits raise fresh questions as key clinical programs continue.
DNLIPositive Net Change BIIBNegative Net Change RHHBYPositive Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
RHHBY's Gazyva Gets FDA Priority Review for Label Expansion
by Zacks Equity Research
Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.
RHHBYPositive Net Change NVONegative Net Change LLYPositive Net Change NRIXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Newsmax (NMAX) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
NMAXNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio?
by Ekta Bagri
BMY's FDA filing for mezigdomide in relapsed or refractory multiple myeloma marks another step in advancing its protein degrader pipeline.
BMYPositive Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
New Strong Sell Stocks for July 14th
by Zacks Equity Research
AZ, AISP and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 14th, 2026.
AZNegative Net Change BCDANegative Net Change AISPNegative Net Change
biotechnology